RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Inflammatory bowel disease increases the risks of deep vein thrombosis and pulmonary embolism in the hospitalized patients: a nationwide cohort study.

BACKGROUND & AIMS: We conducted a nationwide, population-based cohort study to evaluate the effects of inflammatory bowel disease (IBD) on the risks of developing deep vein thrombosis (DVT) and pulmonary embolism (PE) in Taiwan.

METHODS: We randomly selected the study cohort with IBD from the National Health Insurance (NHI) database (N = 23.74 million) and the control cohort without IBD who was frequency-matched the study cohort based on age, sex, and index year to each IBD patient between 2000 and 2010. Using a follow-up period ending in 2011, we analyzed the risks of DVT and PE using Cox proportional hazard regression analyses.

RESULTS: The 11 445 IBD patients and 45 780 controls were followed 65 256 and 293 377 person-years, respectively. After adjusting for age, sex, and comorbidities, the risks of IBD patients developing DVT and PE was 1.98-fold and 1.80-fold higher, respectively, than those of the comparison cohort. The IBD patients presenting with 2 or more annual hospitalizations exhibited a significantly greater risk of developing DVT (adjusted hazard ratio [HR] 32.9, 95% confidence interval [CI] 20.5-52.8) and PE (adjusted HR = 24.2, 95% CI = 11.1-52.9) than did the comparison cohort. Women with IBD showed a significantly greater risk of DVT and PE than did the comparison cohort (adjusted HR = 1.80, 95% CI = 1.18-2.78 for DVT and adjusted HR=2.08, 95% CI = 1.14-3.80 for PE respectively).

CONCLUSION: The risks of DVT and PE are significantly higher in IBD patients compared with risks in the general population.

WHAT IS CURRENT KNOWLEDGE: Thromboembolic complications are easily overlooked in IBD patients.

WHAT IS NEW HERE: The risks of DVT and PE are significantly higher in IBD patients.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app